Literature DB >> 17046829

Srcasm corrects Fyn-induced epidermal hyperplasia by kinase down-regulation.

Weijie Li1, Christine Marshall, Lijuan Mei, Joel Gelfand, John T Seykora.   

Abstract

Src family tyrosine kinases (SFKs) are important regulators of epithelial cell growth and differentiation. Characterization of cellular mechanisms that regulate SFK activity will provide insights into the pathogenesis of diseases associated with increased SFK activity. Keratin 14-Fyn (K14) transgenic mice were derived to characterize the effect of Fyn on epidermal growth and differentiation in vivo. The epidermis of K14-Fyn mice is thickened, manifests prominent scale, and exhibits features consistent with hyperproliferation. Increased epidermal Fyn levels correlate with activation of p44/42 MAP kinases, STAT-3, and PDK-1, key signaling molecules that promote epithelial cell growth. The Src-activating and signaling molecule (Srcasm) is a substrate of SFKs that becomes tyrosine-phosphorylated downstream of the EGF receptor. In vitro, increased Srcasm levels promote activation of endogenous Fyn and keratinocyte differentiation. To study the in vivo effect of Srcasm upon Fyn, double transgenic lines were derived. K14-Fyn/Srcasm transgenic mice did not manifest the hyperproliferative phenotype. In contrast, K14-Fyn/Srcasm-P transgenic mice, which express a nonphosphorylatable Srcasm mutant, maintained the hyperproliferative phenotype. Resolution of the hyperproliferative phenotype correlated with reduced Fyn levels in vivo in three experimental systems: transgenic mice, primary keratinocytes, and cell lines. Biochemical studies revealed that Srcasm-dependent Fyn down-regulation requires Fyn kinase activity, phosphorylation of Srcasm, and the Srcasm GAT domain. Therefore, Srcasm is a novel regulator of Fyn promoting kinase down-regulation in a phosphorylation-dependent manner. Srcasm may act as a molecular "rheostat" for activated SFKs, and cellular levels of Srcasm may be important for regulating epithelial hyperproliferation associated with increased SFK activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17046829      PMCID: PMC3099404          DOI: 10.1074/jbc.M606583200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

1.  Src family kinase inhibitors block amphiregulin-mediated autocrine ErbB signaling in normal human keratinocytes.

Authors:  Sanjay Kansra; Stefan W Stoll; Jessica L Johnson; James T Elder
Journal:  Mol Pharmacol       Date:  2004-12-22       Impact factor: 4.436

2.  Interactions of TOM1L1 with the multivesicular body sorting machinery.

Authors:  Rosa Puertollano
Journal:  J Biol Chem       Date:  2004-12-15       Impact factor: 5.157

3.  Sustained activation of the mitogen-activated protein kinase pathway. A mechanism underlying receptor tyrosine kinase specificity for matrix metalloproteinase-9 induction and cell migration.

Authors:  L J McCawley; S Li; E V Wattenberg; L G Hudson
Journal:  J Biol Chem       Date:  1999-02-12       Impact factor: 5.157

4.  Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model.

Authors:  Shigetoshi Sano; Keith Syson Chan; Steve Carbajal; John Clifford; Mary Peavey; Kaoru Kiguchi; Satoshi Itami; Brian J Nickoloff; John DiGiovanni
Journal:  Nat Med       Date:  2004-12-12       Impact factor: 53.440

5.  Elevated epidermal growth factor receptor gene copy number and expression in a squamous carcinoma cell line.

Authors:  G T Merlino; Y H Xu; N Richert; A J Clark; S Ishii; S Banks-Schlegel; I Pastan
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

6.  Absence of genetic alteration at codon 531 of the human c-src gene in 479 advanced colorectal cancers from Japanese and Caucasian patients.

Authors:  Y Daigo; Y Furukawa; T Kawasoe; H Ishiguro; M Fujita; S Sugai; S Nakamori; G J Liefers; R A Tollenaar; C J van de Velde; Y Nakamura
Journal:  Cancer Res       Date:  1999-09-01       Impact factor: 12.701

7.  Srcasm modulates EGF and Src-kinase signaling in keratinocytes.

Authors:  Weijie Li; Christine Marshall; Lijuan Mei; Leonard Dzubow; Chrysalene Schmults; Michael Dans; John Seykora
Journal:  J Biol Chem       Date:  2004-12-03       Impact factor: 5.157

8.  Activating SRC mutation in a subset of advanced human colon cancers.

Authors:  R B Irby; W Mao; D Coppola; J Kang; J M Loubeau; W Trudeau; R Karl; D J Fujita; R Jove; T J Yeatman
Journal:  Nat Genet       Date:  1999-02       Impact factor: 38.330

9.  Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis.

Authors:  Keith Syson Chan; Steve Carbajal; Kaoru Kiguchi; John Clifford; Shigetoshi Sano; John DiGiovanni
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

10.  c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor.

Authors:  G Levkowitz; H Waterman; E Zamir; Z Kam; S Oved; W Y Langdon; L Beguinot; B Geiger; Y Yarden
Journal:  Genes Dev       Date:  1998-12-01       Impact factor: 11.361

View more
  15 in total

1.  Curcuminoids activate p38 MAP kinases and promote UVB-dependent signalling in keratinocytes.

Authors:  Elias E Ayli; Susanne Dugas-Breit; Weijie Li; Christine Marshall; Liang Zhao; Marc Meulener; Thomas Griffin; Joel M Gelfand; John T Seykora
Journal:  Exp Dermatol       Date:  2010-04-20       Impact factor: 3.960

2.  Activation of Src-family tyrosine kinases in hyperproliferative epidermal disorders.

Authors:  Elias E Ayli; Weijie Li; Tamu T Brown; Agnieszka Witkiewicz; Rosalie Elenitsas; John T Seykora
Journal:  J Cutan Pathol       Date:  2008-03       Impact factor: 1.587

3.  Smooth muscle contraction and growth of stromal cells in the human prostate are both inhibited by the Src family kinase inhibitors, AZM475271 and PP2.

Authors:  Yiming Wang; Christian Gratzke; Alexander Tamalunas; Beata Rutz; Anna Ciotkowska; Frank Strittmatter; Annika Herlemann; Sophie Janich; Raphaela Waidelich; Chunxiao Liu; Christian G Stief; Martin Hennenberg
Journal:  Br J Pharmacol       Date:  2016-11-01       Impact factor: 8.739

4.  Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration.

Authors:  Vipin Yadav; Mitchell F Denning
Journal:  Mol Carcinog       Date:  2010-12-10       Impact factor: 4.784

Review 5.  From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma.

Authors:  Vladimir Ratushny; Michael D Gober; Ryan Hick; Todd W Ridky; John T Seykora
Journal:  J Clin Invest       Date:  2012-02-01       Impact factor: 14.808

6.  Decreased Srcasm expression in esophageal squamous cell carcinoma in a Chinese population.

Authors:  Yu Qi; Xin Li; Liang Zhao; John T Seykora
Journal:  Anticancer Res       Date:  2010-09       Impact factor: 2.480

7.  Tom1l2 hypomorphic mice exhibit increased incidence of infections and tumors and abnormal immunologic response.

Authors:  Santhosh Girirajan; Paula M Hauck; Stephen Williams; Christopher N Vlangos; Barbara B Szomju; Sara Solaymani-Kohal; Philip D Mosier; Kimber L White; Kathleen McCoy; Sarah H Elsea
Journal:  Mamm Genome       Date:  2008-03-15       Impact factor: 2.957

8.  Srcasm inhibits Fyn-induced cutaneous carcinogenesis with modulation of Notch1 and p53.

Authors:  Liang Zhao; Weijie Li; Christine Marshall; Thomas Griffin; Matthew Hanson; Ryan Hick; Tzvete Dentchev; Erik Williams; Adrienne Werth; Christopher Miller; Hasan Bashir; Warren Pear; John T Seykora
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

9.  Decreased Srcasm expression in hyperproliferative cutaneous lesions.

Authors:  Marc C Meulener; Elias E Ayli; Rosalie Elenitsas; John T Seykora
Journal:  J Cutan Pathol       Date:  2009-03       Impact factor: 1.587

10.  Mouse Fyn induces pseudopodium formation in Chinese hamster ovary cells.

Authors:  Lei An; Shengnan Liu; Wei Zhang; Yamei Zhang; Yingxue Huang; Xinde Hu; Shulin Chen; Shanting Zhao
Journal:  J Vet Sci       Date:  2013-12-27       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.